Scoop: With its NDA in limbo, Ironshore execs shuttered the ADHD biotech
A year ago Ironshore Pharmaceuticals execs trumpeted the news that they had lined up $200 million in financing to launch a new ADHD drug …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
